Table 1. Relative risk of etomidate-induced adrenal insufficiency and mortality in septic patients in meta-analysesA.
| Citation | Studies included | Adrenal insufficiency | Mortality |
|---|---|---|---|
| (17) | 21 prospective or retrospective studies | RR 1.70 (1.55-1.87), P<0.0001, I2=93% | RR 1.22 (1.11-1.35), P<0.0001, I2=74% |
| (18) | 10 prospective (for mortality and adrenal insufficiency) or retrospective (adrenal insufficiency only) studies | RR 1.33 (1.22-1.46), no P value given, I2=43.9%; RR 1.35 (1.24-1.47), no P value given, I2=0% in RCT’s only | RR 1.20 (1.02-1.42), no P value given, I2=4.9%; RR 1.26 (1.06-1.50), no P value given, I2=11.6% in RCT’s only |
| (19) | 18 prospective or retrospective studies | RR 1.42 (1.22-1.64), P<0.00001 | RR 1.20 (0.84-1.72), I2=0%, P=0.31 in RCT’s only |
A, results for pooled analyses (i.e., randomized controlled trials and observational studies) unless otherwise noted.